Full-Time

Senior Cybersecurity Engineer

Posted on 12/13/2025

Travere Therapeutics

Travere Therapeutics

501-1,000 employees

Develops and commercializes rare-disease therapies

Compensation Overview

$128k - $165k/yr

San Diego, CA, USA

In Person

Must be onsite in San Diego; travel up to 10% domestic.

Category
IT & Security (1)
Required Skills
PowerShell
Bash
Microsoft Azure
Python
AWS
Risk Management
Linux/Unix
Requirements
  • Bachelor's degree in related Computer Science discipline. Equivalent combination of education and applicable job experience may be considered.
  • 6–8+ years of hands-on cybersecurity engineering or Security Operations Center experience.
  • CISSP certification required. OSCP, GCIH, or GCIA (or equivalent) preferred.
  • Prior experience in a regulated industry (i.e. life sciences, pharma, biotech, fintech).
  • Familiarity with SOX, GxP, ISO 27001, and other security/compliance standards.
  • Strong command of NIST frameworks and security operations best practices.
  • Experience with Okta, Azure/Entra ID, Delinea “Secret Server”, Microsoft Defender, Wiz CNAPP, Cylance/Aurora, Mimecast, Palo Alto.
  • Operating in hybrid cloud environments (Windows, Linux, AWS, Azure).
  • Scripting/automation experience with PowerShell, Python, or Bash.
  • Ability to travel up to 10% domestic.
  • All positions have an essential job function to be able to perform face to face work with colleagues and/or onsite in San Diego. No role is expected to be 100% remote.
Responsibilities
  • Support and enhance the company’s cybersecurity program in alignment with NIST CSF 2.0 and related frameworks (e.g., NIST SP 800-53, 800-171).
  • Manages Travere’s NIST roadmap, driving progress and ensuring it remains current.
  • Oversees Travere’s SOC services, including: Managing escalations, tuning detection logic; Investigating security alerts and incidents; Enhancing SOC workflows and playbooks.
  • Operate and maintain key security tools: EDR, SIEM, firewalls, vulnerability scanners, etc.; Ensure integration and effectiveness across platforms.
  • Administer identity and access management using Okta and Microsoft Entra ID (Azure AD): Enforce MFA, SSO, and lifecycle access controls; Oversees the integration and management for any new identity and access management solutions within the infrastructure.
  • Manage Travere’s Privileged Access Management (PAM) platform – Delinea “Secret Server”: Onboarding privileged accounts, policy enforcement, and ongoing maintenance.
  • Perform vulnerability assessments and support remediation efforts with IT and cloud teams.
  • Document incidents, systems, tooling configurations, and audit evidence.
  • Support SOX, GxP, data privacy, and other compliance initiatives with technical input and control documentation.
Desired Qualifications
  • Demonstrated ability to develop and mature enterprise security roadmaps.
  • Experience aligning cybersecurity initiatives with overall business strategy and risk tolerance.
  • Experience with third-party/vendor risk management in regulated industries.
  • Proven ability to translate technical risks into business terms for executives and auditors.
  • Familiarity with emerging technologies such as zero trust, OT/IoT security, and AI/ML applications in cybersecurity.
  • Experience with Data Security Posture Management (DSPM) or related data discovery/classification tools to ensure visibility and protection of sensitive data across cloud and on-prem environments.
  • Strong professional experience in a similar role within the pharmaceutical industry, preferred.

Travere Therapeutics develops and commercializes therapies for rare diseases, especially kidney and metabolic disorders. It has commercial products Thiola and Thiola EC for cystinuria and Chenodal for gallstones, with a pipeline that includes sparsentan for focal segmental glomerulosclerosis and IgA nephropathy. The company generates revenue from the sale of its products and supports patients through a dedicated patient assistance program. Its approach centers on identifying and delivering treatments for rare diseases, combining commercialization with ongoing drug development.

Company Size

501-1,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

2008

Simplify Jobs

Simplify's Take

What believers are saying

  • FILSPARI Q1 2026 sales hit $105.2 million, up 88% year-over-year.
  • FSGS approval expands US addressable market beyond 100,000 patients.
  • Chugai submits sparsentan NDA in Japan 2026, triggering milestone payments.

What critics are saying

  • Robbins Geller investigates Travere for securities violations since January 2026.
  • Ligand claims 9% royalty on all worldwide FILSPARI sales.
  • Novartis atrasentan Phase III threatens 20-30% FILSPARI market share.

What makes Travere Therapeutics unique

  • FILSPARI is first FDA-approved therapy for FSGS in patients aged 8 and older.
  • FILSPARI leads IgAN market as most prescribed FDA-approved medicine.
  • Pegtibatinase advances as novel Phase 3 enzyme replacement for classical homocystinuria.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

Disability Insurance

401(k) Company Match

Paid Vacation

Wellness Program

Company Equity

Company News

Yahoo Finance
Apr 14th, 2026
Travere's FILSPARI receives FDA approval for FSGS, earns Ligand 9% royalty on sales

Ligand Pharmaceuticals' partner Travere Therapeutics has received FDA approval for FILSPARI (sparsentan) to treat focal segmental glomerulosclerosis (FSGS) in adult and paediatric patients aged eight and older without nephrotic syndrome. FILSPARI becomes the first and only FDA-approved medicine for FSGS, a rare kidney disorder and leading cause of kidney failure. The approval expands FILSPARI beyond IgA nephropathy, where it is already the most commonly prescribed FDA-approved medicine. Ligand is entitled to a 9% royalty on worldwide net sales. Travere estimates the addressable US population exceeds 30,000 individuals with FSGS without nephrotic syndrome. In the Phase 3 DUPLEX Study, FILSPARI demonstrated a statistically significant 48% reduction in proteinuria compared to 27% for irbesartan in patients without nephrotic syndrome.

Yahoo Finance
Apr 13th, 2026
FDA fully approves FILSPARI for FSGS, first treatment for rare kidney disease affecting 30K US patients

Travere Therapeutics announced that the FDA has granted full approval for FILSPARI (sparsentan) to reduce proteinuria in adults and children aged 8 years and older with focal segmental glomerulosclerosis (FSGS) who do not have nephrotic syndrome. FILSPARI is the first and only FDA-approved medicine for FSGS. The approval expands FILSPARI's addressable population to more than 100,000 patients in the US, including over 30,000 with FSGS. The drug is already the most commonly prescribed FDA-approved medicine for IgA nephropathy. In the Phase 3 DUPLEX Study, FILSPARI demonstrated a statistically significant 46% reduction in proteinuria compared to 30% for irbesartan. In patients without nephrotic syndrome specifically, the reduction was 48% versus 27%. The medicine was generally well tolerated across adult and paediatric patients.

The Motley Fool
Jan 25th, 2026
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? | The Motley Fool

This biopharma firm targets rare diseases with both approved therapies and a pipeline of clinical-stage treatments.

The Motley Fool
Jan 24th, 2026
Palisades Investment buys $5.3M stake in Travere Therapeutics as shares surge 51%

Palisades Investment Partners initiated a new position in Travere Therapeutics worth $5.26 million, acquiring 137,768 shares in the fourth quarter of 2025, according to an SEC filing. The stake represents 1.99% of the fund's $264.72 million in reportable US equity assets. Travere Therapeutics, a biotechnology company specialising in rare disease therapies, has seen its shares rise 50.89% over the past year to $27.87. The company's revenue surged to $164.9 million in the third quarter, driven by a 155% year-over-year increase in sales of its FILSPARI drug to $90.9 million. The timing of Palisades' investment coincided with FDA review of FILSPARI for potential expanded approval in focal segmental glomerulosclerosis treatments, suggesting confidence in the company's growth prospects.

GlobeNewswire
Jan 13th, 2026
TVTX ALERT: Investigation Launched into Travere Therapeutics, Inc., RGRD Law Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm

TVTX ALERT: investigation launched into Travere Therapeutics, Inc., RGRD law attorneys encourage investors and potential witnesses to contact law Firm. SAN DIEGO, Jan. 13, 2026 (GLOBE NEWSWIRE) - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Travere Therapeutics, Inc. (NASDAQ: TVTX). If you have information that could assist in the Travere investigation or if you are a Travere investor who suffered a loss and would like to learn more, you can provide your information here: You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. THE COMPANY: Travere is a biopharmaceutical company that develops therapies for people living with rare kidney and metabolic diseases in the United States. THE INVESTIGATION: Robbins Geller is investigating whether Travere and certain of its top executives made materially false and/or misleading statements and/or omitted material information regarding Travere's business and operations. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases - more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever - $7.2 billion - in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices.

INACTIVE